Trial Profile
A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks (Treximet).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Naproxen sodium/sumatriptan (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Aug 2009 Results published in Cephalalgia.
- 01 Apr 2009 Actual patient number 623 added as reported by ClinicalTrials.gov.
- 18 Sep 2008 New trial record.